A new way to control liver damage in fatty liver disease

A novel pathway controls liver injury in NASH

['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · NIH-11084431

This study is looking into how nonalcoholic steatohepatitis (NASH) damages the liver and aims to find new ways to help treat it, which could be really helpful for people living with this condition.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorUNIVERSITY OF TEXAS HLTH SCIENCE CENTER (nih funded)
Locations1 site (SAN ANTONIO, UNITED STATES)
Trial IDNIH-11084431 on ClinicalTrials.gov

What this research studies

This research investigates the underlying mechanisms of liver injury caused by nonalcoholic steatohepatitis (NASH), a serious condition that can lead to cirrhosis and liver cancer. The study focuses on understanding how liver cell death occurs and how it can be controlled, which is crucial for developing new treatments. By examining the molecular pathways involved in this process, researchers aim to identify potential therapeutic targets that could reverse the effects of NASH. Patients with NASH may benefit from this research as it seeks to uncover new strategies for treatment.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with nonalcoholic steatohepatitis (NASH) who are experiencing liver injury.

Not a fit: Patients with liver conditions unrelated to NASH or those who do not have liver injury may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapies for patients suffering from nonalcoholic steatohepatitis, potentially reversing liver damage.

How similar studies have performed: Previous research has shown promise in understanding liver injury mechanisms in similar conditions, indicating potential for success in this novel approach.

Where this research is happening

SAN ANTONIO, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.